Small Molecule Drug Discovery Outsourcing Market (2026 - 2033) Size, Share & Trends Analysis Report By Workflow (Lead Identification & Candidate Optimization, Preclinical Development), By Service, By Therapeutics Area, By End-use, By Region, And Segment Forecasts

Small Molecule Drug Discovery Outsourcing Market Summary

The global small molecule drug discovery outsourcing market size was estimated at USD 4.94 billion in 2025 and is projected to reach USD 10.62 billion by 2033, growing at a CAGR of 10.2% from 2026 to 2033. The market is driven by rising research and development expenses, an increasing need for drug development, and a transition toward virtual pharmaceutical models.

Some other factors contributing to market growth are rising number of registered studies, growing approval of small molecule drug, advancements in medical technology, an upsurge in diseases under investigation, and the imperative for novel treatments.

Moreover, the trend of outsourcing in the pharmaceutical industry is gaining momentum as companies recognize the benefits of acquiring additional competencies essential for successful drug development and commercialization. As outsourcing not only provides specialized expertise but also helps improve cash flow management and offers significant manufacturing advantages, including the reduction of investment risks.  Besides, developing costly in-house capabilities for early-stage technologies and products involves considerable risks throughout the development process. These factors have led to outsourcing as an emerging risk-averse alternative for product innovations. Moreover, companies often face challenges in determining the necessary scale for current and future product offerings or market penetration, which complicates the design and scaling of in-house manufacturing. As a result, outsourcing has become a preferred for products innovation.

Furthermore, innovative technologies, the rising prevalence of chronic and infectious diseases, and the growing need for new therapies support market growth. Advances such as artificial intelligence, machine learning, and high-throughput screening are streamlining the processes of hit identification and lead optimization, supporting the market growth. Also, advancement of precision medicine and AI-driven screening methods has further enhanced the efficiency of the discovery process. Similarly, advancements in drug design, predictive modeling, and precision medicine are enhancing the contributions of outsourcing partners in the early stages of drug discovery and development. Such factors are expected to drive the market growth over the estimated time period.

Opportunity Analysis

The small molecule drug discovery outsourcing market is experiencing significant growth opportunities driven by the increasing complexity of drug research, a rising demand for cost-effective innovations, and a shift towards virtual pharmaceutical models. As global drug pipelines expand, more companies are outsourcing early-stage activities such as target validation, hit identification, and lead optimization to specialized contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs).

This strategy aims to accelerate development timelines and reduce fixed costs. Moreover, the market has its major opportunity in the application of AI-powered drug discovery platforms, which enhance the efficiency of candidate screening and selection. Besides, the growing focus on rare diseases, oncology, and central nervous system (CNS) disorders is driving demand for high-throughput and personalized discovery methods, creating new growth opportunities for specialized CROs. Furthermore, emerging regions like India, China, and Eastern Europe are becoming attractive outsourcing destinations due to their skilled workforce and cost advantages. In addition, regulatory harmonization fuels the collaboration across borders. Also, mid-sized biotech firms that lack internal capabilities are increasingly turning to comprehensive outsourcing solutions. Similarly, a rise in venture capital investment and strategic partnerships between CROs and pharmaceutical companies is accelerating innovation in the market. The integration of digital tools, predictive modeling, and rapid synthesis techniques positions outsourcing as a pivotal element in the future landscape of small molecule drug discovery.

Impact of U.S. Tariffs on the Global Small Molecule Drug Discovery Outsourcing (CRO) Market

The implementation of U.S. tariffs on imported goods, notably from countries such as China, has affected the global small molecule drug discovery outsourcing market in various ways. Many pharmaceutical and biotech companies in the U.S. depend on CROs in China and India for early-stage drug discovery due to their cost advantages and technical proficiency. However, the introduction of tariffs has resulted in increased costs for raw materials, reagents, and laboratory equipment obtained from these regions, thereby increasing operational expenses for both U.S. companies and their overseas partners. This factor has led companies to reassess their supply chain strategies and consider diversifying their outsourcing options to avoid regions impacted by tariffs.

However, in response due to U.S. tariffs, many organizations are relocating parts of their discovery operations to countries such as India, Eastern Europe, and Southeast Asia, which remain unaffected by U.S. tariffs. In addition, domestic CROs are finding a slight competitive edge as pharmaceutical clients look to decrease their exposure to international trade uncertainties. Thus, this trend has not completely alleviated the financial strain caused by higher import duties and logistics delays. Overall, the tariffs have accelerated the strategic evaluations of outsourcing models, encouraging the development of regional partnerships, dual sourcing strategies, and nearshoring alternatives to enhance resilience in global early-stage drug discovery operations.

Technological Advancements

Technological advancements are revolutionizing small molecule drug discovery outsourcing, making research faster, more efficient, and cost-effective. Key innovations in Artificial Intelligence and Machine Learning (AI/ML) are pivotal, as they enhance the prediction of target-ligand interactions, analyze intricate datasets, and optimize compound libraries. This significantly speeds up hit identification and lead optimization processes. Besides, high-throughput screening (HTS) is another critical factor allowing CROs to assess compounds using automated, miniaturized assays, thereby improving the success rates of hit discovery. Moreover, cloud-based collaborative platforms facilitate real-time data sharing, project tracking, and communication between sponsors and CROs, which promotes transparency & accelerates decision-making across global teams. In addition, computational chemistry and molecular modeling tools assist in virtual screening and lead refinement by predicting how compounds behave, which also reduces reliance on lengthy lab procedures. Moreover, automated medicinal chemistry platforms streamline the process by optimizing compound synthesis and reaction processes through robotics and AI-driven systems, enabling rapid Structure-Activity Relationship (SAR) cycles. For instance, in October 2024, AION Labs announced the launch of ProPhet, a startup leveraging artificial intelligence to improve small molecule identification in drug discovery. The company aims to streamline and advance early-stage drug development by targeting proteins, while significantly reducing the time and cost associated with identifying potential drug candidates for these targets.

Thus, these technologies empower outsourcing providers to produce high-quality results, shorten development timelines, and offer scalable solutions to pharmaceutical and biotech clients seeking innovation in small molecule discovery. They facilitate agile, data-driven strategies, positioning CROs as essential partners in expediting preclinical pipelines and enhancing overall R&D productivity.

Pricing Model Analysis

The small molecule drug discovery outsourcing market offers a variety of pricing models designed to suit project scope, risk-sharing requirements, and service complexity. Milestone-based pricing is commonly utilized, linking payments to specific R&D milestones such as target validation or lead optimization. This model supports accountability and aligns the incentives of Contract Research Organizations (CROs) with the objectives of sponsors. The fixed-fee model is suitable for tasks such as compound synthesis providing budget certainty, however limited flexibility for any changes in the project. Value-based pricing, while less prevalent, connects compensation to measurable scientific or commercial outcomes, promoting high performance and innovation, especially in high-value therapeutic areas. However, it requires effective performance metrics and a high level of trust between partners. Moreover, the subscription or retainer model allows sponsors to pay a recurring fee for ongoing access to CRO expertise and infrastructure, which is particularly beneficial for virtual pharma companies and biotechs that seek flexible, long-term collaboration.  Thus, sponsors are increasingly adopting a blend of these pricing models to effectively balance cost, performance, and risk throughout the drug discovery process.

Market Concentration & Characteristics

The small molecule drug discovery outsourcing market growth stage is high, and growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion

The landscape of small molecule drug discovery outsourcing is evolving driven by advancements in AI-powered screening, structure-based design, and predictive analytics. Contract Research Organizations (CROs) are increasingly using digital platforms, machine learning, and automation to improve the processes of hit identification and lead optimization. In addition, by incorporating multi-omics data and computational chemistry techniques, the discovery of new compounds is accelerated resulting in shorter time-to-market and enhanced quality and success rates of drug candidates.

The number of mergers and acquisitions is increasing as Contract Research Organizations (CROs), and Contract Development and Manufacturing Organizations (CDMOs) seek to broaden their discovery capabilities and expand their geographical reach. Larger companies are acquiring specialized companies that provide AI technologies, early-stage discovery assets, or significant therapeutic knowledge. These factors further improve service offerings, optimize operations, and enhance relationships with clients further fueling the comprehensive outsourcing solutions and boosting market competitiveness in discovery, development, and regulatory services.

Global regulatory bodies such as the FDA, EMA, and PMDA are placing a strong focus on data integrity, reproducibility, and adherence to compliance standards in early-stage discovery efforts. As a result, CROs are increasingly investing in robust quality systems, validated platforms, and secure data management practices. The alignment of ICH and GxP guidelines is enhancing transparency, promoting cross-border collaborations, and allowing for quicker regulatory approvals for outsourced preclinical discovery initiatives.

CROs are broadening their service offerings from fundamental medicinal chemistry to comprehensive drug discovery, which now encompasses AI modeling, in silico ADMET, bioassays, and studies that facilitate Investigational New Drug (IND) applications. The incorporation of platform technologies such as high-throughput screening and synthetic biology enables sponsors to utilize a range of capabilities in a single location. This extensive service expansion improves operational efficiency and accommodates intricate discovery processes in therapeutic fields like oncology and central nervous system disorders.

Outsourcing providers are increasingly expanding into the Asia-Pacific region, Eastern Europe, and Latin America to address growing demand and reduce geopolitical risks. In addition, countries such as India and China are at the forefront in terms of capacity and cost-effectiveness, while Eastern Europe provides advantageous access to EU markets. At the same time, CROs based in the U.S. and EU are enhancing their domestic operations to align with reshoring trends. This regional expansion further enhances global presence and supply chain resilience.

Workflow Insights

The lead identification & candidate optimization segment dominated the market, accounting for a revenue share of 32.25% in 2025. The segment growth is driven by higher R&D costs, demand for faster timelines, the growing adoption of AI technology, complex therapies, and the rising demand for high-quality preclinical candidates. Besides, the stage plays a major role for Contract Research Organizations (CROs) to assist pharmaceutical companies in identifying and improving promising compounds further supporting the market growth. Moreover, growing need for therapies in oncology, CNS disorders, and infectious diseases is driving the small molecule drug discovery outsourcing market. In addition, CROs utilize lead identification and candidate optimization, high-throughput screening, and computational chemistry to identify active molecules and improve their drug-like characteristics. Thus, as the with the rising drug targets and requirement for faster preclinical development is expected to drive the market over the estimated time period.

The preclinical development segment is expected to grow at the fastest CAGR over the forecast period. Preclinical development plays a crucial role in the outsourcing of small molecule drug discovery, focusing on assessing safety, toxicity, and pharmacokinetics prior to clinical trials. This phase is increasingly outsourced due to the rising complexity of regulatory requirements, cost constraints, and the need for expedited Investigational New Drug (IND) submissions. Besides, pharmaceutical and biotech companies collaborate with Contract Research Organizations (CROs) to leverage specialized expertise, access advanced in vivo models, and utilize GLP-compliant facilities. Moreover, factors such as increased pipeline activity, an emphasis on rare and complex diseases, and the transition toward virtual R&D models are expected to support the market growth. Thus, by outsourcing pre-clinical development, companies can achieve greater flexibility, reduce risk, and accelerate the progression of drug candidates into human trials. Such factors are expected to drive market growth.

Service Insights

The chemistry services segment dominated the market with largest revenue share in 2025, attributed to the increasing complexity of drug design and the need for rapid synthesis of diverse chemical libraries. Chemistry services play a vital role in small molecule drug discovery outsourcing, encompassing hit synthesis, lead optimization, and custom compound development. By outsourcing, pharmaceutical and biotech companies can leverage the expertise of skilled chemists, access scalable infrastructure, and utilize specialized technologies, all without making significant internal investments. Moreover, factors such as cost efficiency, shorter development timelines, and a growing emphasis on complex therapeutic areas such as oncology is expected to support market growth. Furthermore, with the growing number of virtual pharma models, the chemistry outsourcing services is expected to support market growth.

On the other hand, the biology services segment is expected to grow significantly during the forecast period. Biology services in small molecule drug discovery outsourcing encompass target validation, assay development, mechanism-of-action studies, and both in vitro and in vivo efficacy testing. These services are widely used to assess the biological relevance and understanding drug nature. Besides, the growing demand for specialized disease models, increasing complexity of therapeutic targets, and the necessity for preclinical decisions are propelling the trend towards outsourcing companies. Moreover, pharmaceutical and biopharmaceutical companies are turning to contract research organizations (CROs) to gain access to advanced bioassays, cell-based platforms, and translational models, particularly in fields such as oncology and central nervous system disorders. This strategic facilitates cost-effective, flexible, and data-driven drug discovery processes, further supporting the market growth.

End-use Insights

The pharmaceutical & biotechnology companies segment accounted for the largest market share in 2025. Pharmaceutical and biotechnology firms are increasingly opting for small molecule drug discovery outsourcing to speed up research and development, lower expenses, and tap into specialized expertise. As the demand for innovative therapies grows, outsourcing allows for more flexible resource management and access to cutting-edge technologies such as artificial intelligence, high-throughput screening, and computational modeling. Biotech companies, typically working with limited in-house resources, depend on Contract Research Organizations (CROs) for comprehensive discovery support. Similarly, pharmaceutical companies leverage outsourcing to broaden their pipelines, mitigate risks, and prioritize internal resources for critical or advanced-stage projects. Thus, such factors are expected to drive the market over the estimated time period.

The academic institute’s segment is expected to grow at a significant CAGR during the forecast period. Academic institutes are increasingly shifting towards outsourcing of small molecule drug discovery, offering early-stage research, novel targets, and innovative screening methods. Besides, limited infrastructure and funding often compel these institutes to collaborate with Contract Research Organizations (CROs) for medicinal chemistry, ADMET profiling, and lead optimization. Besides, rising trend towards translational research funding, government-backed innovation initiatives, and collaborative models with industry are expected to support the market. By outsourcing, academic teams can expedite discovery timelines, bridge the commercialization gap, and amplify the influence of basic research on therapeutic development.

Therapeutics Area Insights

The respiratory system segment accounted for the largest market share in 2025. The respiratory therapeutic area in small molecule drug discovery outsourcing is expanding due to rising cases of asthma, COPD, pulmonary hypertension, and post-COVID complications. Chronic Respiratory Diseases (CRDs) have increased globally, which has led pharmaceutical and biopharmaceutical companies to rely on CROs and CDMOs for expertise in pulmonary models, inhalation delivery, and biomarker-based screening. Moreover, factors such as the rising need for targeted therapies, faster development timelines, and regulatory demands for safety is expected to support the market over the estimated time period. Technological advancements and novel drug development approaches are further enabling faster, more effective discovery of respiratory treatments to address the growing global burden of respiratory diseases efficiently.

The oncology segment is expected to grow at a significant CAGR during the forecast period. Oncology continues to be a major area of focus in small molecule drug discovery outsourcing, driven by the significant global cancer burden and the pressing demand for targeted therapies. Pharmaceutical companies often turn to outsourcing to leverage specialized cancer biology platforms, biomarker-driven screening processes, and innovative compound libraries. Key factors motivating this trend include increasing R&D costs, the complexities of tumor biology, and the growing need for personalized treatment options. Contract Research Organizations (CROs) provide advanced in vitro and in vivo oncology models, facilitating quicker lead identification and optimization while mitigating risks in the early stages of drug development. Moreover, private players provide biochemical, biophysical, and cellular assay systems for oncology targets, which include tumor microenvironment, tumor metabolism, cancer immunology, and other assays. For instance, U.S. FDA mentioned that as of 2023, the worldwide oncology pipeline mentioned 16 oral medications & 6 injectable drugs, with 6 drugs dedicated to breast cancer and 3 aimed for non-small cell lung cancer.

Regional Insights

North America Small Molecule Drug Discovery Outsourcing Market held a largest share in the global market of 41.11% in 2025, supported by a strong pharmaceutical and biotechnology landscape, innovative research and development infrastructure, and the widespread integration of innovative technologies such as artificial intelligence and high-throughput screening. In addition, countries such as U.S., Canada and Mexico is particularly at the forefront of outsourcing demand, driven by expanding R&D expenditures, a robust pipeline of small molecule therapeutics, and a growing dependence on external contract research organizations (CROs) for early-stage discovery capabilities. Besides, there is an increasing trend in strategic partnerships between pharmaceutical firms and specialized CROs, especially in the fields of oncology and rare diseases. Moreover, rising venture capital investments and the rise of virtual biotech models are further propelling outsourcing practices throughout the preclinical phases of drug discovery.

U.S. Small Molecule Drug Discovery Outsourcing Market Trends

The small molecule drug discovery outsourcing market in the U.S. accounted for the highest market share in the North America market, owing to rising research and development budgets, emerging landscape of biotech startups, and robust capabilities among contract research organizations (CROs). Besides, outsourcing facilitates cost-efficient early-stage services such as target validation, hit screening, and lead optimization. Moreover, advancements in artificial intelligence and automation are streamlining timelines significantly. U.S.-based CROs gain an advantage through their familiarity with regulatory requirements, strong domestic collaborations with pharmaceutical companies, and a wide-ranging global client base, particularly in areas like oncology, neurology, and pipelines for rare diseases.

Canada small molecule drug discovery outsourcing market is expected to grow at a significant CAGR during the forecast period driven by strong collaborations between academia and industry, as well as government support for biotech innovation. Mid-sized contract research organizations (CROs) provide specialized early research services, including medicinal chemistry, bioassays, and computational modeling. Besides, the close proximity to U.S. clients and aligned regulatory standards foster cross-border partnerships. The emphasis on oncology, infectious diseases, and central nervous system (CNS) disorders is driving demand in the country. Furthermore, outsourcing enables Canadian biotech firms to access high-quality discovery services, while international clients gain the advantage of competitive costs and a pool of skilled scientific expertise.

Europe Small Molecule Drug Discovery Outsourcing Market Trends

Europe's medical device CDMO market is evolving rapidly, due to rising CRO hubs in the UK, Germany, France, and Eastern Europe. Besides, sponsors gaining comprehensive drug discovery services, innovative technologies, and streamlined regulatory frameworks is expected to support the market. CROs provide a range of services, including AI-driven hit screening, medicinal chemistry, ADMET profiling, and translational biology tailored for oncology, metabolic disorders, and neurological diseases. Also, collaborative efforts between industry and academic innovators significantly enhance innovation. Moreover, the emergence of virtual biotech models and supportive EU research funding further promote outsourcing, delivering cost-effective and compliant solutions for global clients.

The small molecule drug discovery outsourcing market in Germany held the highest share in 2025. Germany stands out as a pivotal outsourcing hub in Europe recognized for its precision, scientific expertise, and GMP-compliant infrastructure. Contract research organizations (CROs) in the country focus on areas such as medicinal chemistry, computational modeling, ADMET assessment, and bioassays. In addition, robust partnerships with academic institutions and government support drive innovation, particularly in oncology and central nervous system (CNS) research. Moreover, regulatory alignment with the European Medicines Agency (EMA) and global standards attracts multinational clients further contributing to market growth. Germany's outsourcing market is characterized by high-quality services and cutting-edge technologies, providing dependable and efficient drug discovery support throughout Europe and beyond.

The small molecule drug discovery outsourcing market in UK is characterized by top-tier research capabilities, experienced contract research organizations (CROs), and a highly skilled workforce. The range of services offered includes hit identification, medicinal chemistry, bioanalytics, and preclinical biology, particularly in oncology, immunology, and infectious diseases. Besides, the integration of AI and translation platforms enhances productivity within the sector. Strong collaborations with academic institutions and a well-supported biotech ecosystem further elevate service quality. With its regulatory alignment and infrastructure, the country is a preferred outsourcing destination for both European and global pharmaceutical companies.

Asia Pacific Small Molecule Drug Discovery Outsourcing Market Trends

Asia Pacific is amongst the fastest growing region over the forecast period of 2026 to 2033, driven by various factors, such as cost-effective and high-skilled outsourcing destination within the countries such as India, China, and Southeast Asia. Contract research organizations (CROs) in this area provide integrated services, including medicinal chemistry, high-throughput screening (HTS), ADMET analysis, and bioassays, supported by a talented workforce and state-of-the-art laboratories. Strong government incentives and regulatory harmonization are key factors driving this growth. The region is increasingly adopting artificial intelligence and automation technologies. As a result, it attracts global pharmaceutical and biotech companies looking to minimize costs while maintaining high-quality standards, particularly in early-stage discovery for oncology, central nervous system (CNS) disorders, and metabolic diseases.

The small molecule drug discovery outsourcing market in China is witnessing new growth opportunities due to extensive chemistry expertise, increasing investment in biotechnology, and supportive government R&D incentives. Contract research organizations (CROs) provide a wide range of early-phase services, including hit discovery, medicinal chemistry, and preclinical biology. The adoption of artificial intelligence and high-throughput systems is on the rise. Strong local pipelines in oncology and infectious diseases align well with global client needs. In addition, ongoing regulatory reforms and international collaborations are enhancing quality and trust, positioning China as a significant global player in affordable and scalable discovery services.

The small molecule drug discovery outsourcing market in Japan is characterized by rising innovation within contract research organizations (CROs) providing top-tier services in chemistry, biology, and computational fields. There is a strong collaboration between pharmaceutical and biotechnology companies, bolstered by regulatory alignment with the International Council for Harmonisation (ICH) and accelerated approval processes. CROs in Japan focus on oncology, central nervous system (CNS) disorders, and rare diseases, utilizing cutting-edge technologies and AI platforms. With high operational standards, a professional talent pool, and a dedication to quality, Japan has become a trusted outsourcing destination, particularly for domestic sponsors and select international clients.

India small molecule drug discovery outsourcing market has established itself as a leading global destination for small molecule discovery outsourcing, providing a wide range of services, including medicinal chemistry, ADMET, high-throughput screening (HTS), and bioanalytics, all at competitive prices. Contract research organizations (CROs) benefit from a pool of skilled scientists, robust technical expertise, and expanding laboratory infrastructure. The increasing adoption of AI and automation further enhances efficiency. In addition, regulatory convergence and government support for R&D contribute to market growth, making the country as an ideal choice for global pharmaceutical and biotech companies seeking cost-effective, high-volume discovery operations, particularly in early-stage programs.

Latin America Small Molecule Drug Discovery Outsourcing Market Trends

Latin America is emerging as a value-driven outsourcing region, with significant biomedical hubs in Brazil, Mexico, and Argentina. Local CROs provide services in medicinal chemistry, bioassays, and ADMET profiling. Lower labor costs, coupled with improving scientific infrastructure, attract both domestic and international sponsors. Collaborations with regional academic institutions promote translational research. The adoption of outsourcing is on the rise fueled by the cost advantages and strategic diversification pursued by pharmaceutical and biotech companies operating across Latin America is expected to support the market growth.

The small molecule drug discovery outsourcing market in Brazil is expanding driven by growing biotech ecosystem and strong academic collaboration. CROs are offering services in medicinal chemistry, screening, and ADMET evaluation, with an increasing focus on oncology and infectious disease research. Government-sponsored research funding and regulatory alignment enhance the quality of services. Moreover, the country has gained increased attention of sponsors due to its competitive pricing, regional expertise, and expanding scientific capacity, particularly appealing to Latin American and smaller global biotech companies.

MEA Small Molecule Drug Discovery Outsourcing Market Trends

The Middle East & Africa (MEA) medical device CDMO market is witnessing significant growth. Besides, services such as medicinal chemistry and basic biology are expanding market growth. In addition, investments in biotech infrastructure and government-led innovation initiatives are driving the market. Regulatory frameworks are aligning with international standards, fueling confidence among sponsors. The diversification allow outsourcing options allows both global and regional clients to access cost-effective discovery services while supporting the rise of emerging virtual drug discovery initiatives.

South Africa small molecule drug discovery outsourcing market is expanding due to strong translational research and the emergence of biotech clusters. CROs in the region provide services in medicinal chemistry, molecular modeling, and early bioassay development. Government R&D investments in health and infectious disease are further driving growth. While current capabilities are relatively small-scale, regulatory alignment and partnerships with academic institutions support the delivery of high-quality outputs. The country offers affordable discovery services backed by regional expertise, making it an attractive option for both local and global biotech sponsors. Such factors are expected to support the market growth.

The small molecule drug discovery outsourcing market in UAEis experiencing growth, fueled by expanding biotech investment, government innovation strategies, and demand for cost-efficient R&D partnerships. The competitive landscape features global CROs collaborating with regional research hubs and academic institutions. Regulatory operations is strengthening through national health authorities emphasizing clinical compliance, intellectual property protection, and quality standards, supporting international partnerships while ensuring ethical research practices and data integrity.

Key Small Molecule Drug Discovery Outsourcing Company Insights

The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in January 2025, Iktos and Cube Biotech have partnered to identify new small molecule agonists for the Amylin Receptor. This collaboration leverages Iktos' innovative AI-based drug discovery and robotic synthesis capabilities alongside Cube Biotech's cutting-edge native membrane protein technology, NativeMPTM, and their proficiency in purification & biophysical assays.

Recent Developments

• In May 2025, Peptone announced partnership with Evotec to accelerate & scale the development of small molecule treatments targeting intrinsically disordered proteins (IDPs) across various therapeutic fields. This collaboration will enhance the Evotec drug discovery toolbox encompassing drug discovery resources, which include specialized knowledge in oncology and immunology, advanced assay development skills, and cutting-edge screening technologies. This integration likely to complement Peptone's innovative, physics-based methods for analyzing the structural dynamics of IDPs.

• In April 2025, The Icahn School of Medicine at Mount Sinai mentioned the launch of AI Small Molecule Drug Discovery Center, aiming to transform the drug development process through the use of artificial intelligence. This new center will blend artificial intelligence techniques with conventional drug discovery approaches to efficiently and accurately identify and design innovative small-molecule therapeutics. 

• In March 2025, Curia Global, Inc. announced plans to expand its facility in Glasgow, UK, along with ongoing expansion efforts in Albuquerque, NM. This development in Glasgow is part of a multi-year expansion project at Curia’s Albuquerque site, which includes an investment of USD 200 million. The Albuquerque site is expected to introduce two filling lines, adding over 70,000 sq ft. to the extensive 200,000 sq ft. manufacturing area to enhance the phase III clinical & commercial capacity for clients. In addition, the VarioSys Flex Line, designed for small-scale biologics & non-potent small molecules and can process syringes, cartridges, and vials. The company also indicated that the new high-speed vial line is scheduled to begin commissioning in the third quarter of 2025. This high-speed line likely to feature two autoloaded freeze dryers, along with automated vial inspection & labeling/packaging capabilities for vials ranging from 2R to 30R.

Small Molecule Drug Discovery Outsourcing Market Report Scope

Global Small Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, end-use, and region.

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)

  • Target Identification & Screening

  • Target Validation & Functional Informatics

  • Lead Identification & Candidate Optimization

  • Preclinical Development

  • Other Associated Workflow

• Service Outlook (Revenue, USD Million, 2021 - 2033)

  • Chemistry Services

  • Biology Services

• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

  • Respiratory system

  • Pain and Anesthesia

  • Oncology

  • Ophthalmology

  • Hematology

  • Cardiovascular

  • Endocrine

  • Gastrointestinal

  • Immunomodulation

  • Anti-infective

  • Central Nervous System

  • Dermatology

  • Genitourinary System

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical & Biotechnology companies

  • Academic Institutes

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • UAE

    • Saudi Arabia

    • Kuwait

    • Qatar

    • Oman